Aug 5, 2026 09:02AM
Apr 14, 2026 09:02AM
Apr 14, 2026 09:02AM
Mar 31, 2026 08:58AM
Mar 25, 2026 09:02AM
Mar 25, 2026 09:01AM
Mar 17, 2026 09:01AM Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal
Mar 10, 2026 09:02AM
Feb 23, 2026 09:01AM
Feb 16, 2026 09:03AM
Jan 15, 2026 09:02AM
Dec 24, 2025 09:02AM
Oct 16, 2025 09:04AM
Oct 14, 2025 09:03AM Co-PSMA trial achieves primary endpoint
Jul 17, 2025 09:01AM
Jul 17, 2025 09:01AM
Jun 17, 2025 09:04AM
Jun 13, 2025 09:01AM
Jun 5, 2025 09:01AM
May 29, 2025 09:04AM
May 20, 2025 09:02AM Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences
Apr 17, 2025 09:01AM
Apr 15, 2025 09:02AM
Mar 5, 2025 08:44AM
Feb 19, 2025 09:09AM
Jan 28, 2025 09:04AM
Jan 24, 2025 09:02AM
Dec 18, 2024 09:03AM Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical
Oct 16, 2024 09:03AM
Oct 14, 2024 09:02AM
Sep 12, 2024 09:03AM
Aug 22, 2024 09:04AM
Mar 15, 2024 08:58AM
Mar 8, 2024 09:02AM
Dec 22, 2023 09:01AM First patient dosed in Clarity's registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA
Nov 30, 2023 09:16AM
Nov 30, 2023 08:59AM
Nov 29, 2023 08:58AM
Nov 7, 2023 08:58AM
Oct 26, 2023 09:00AM
Oct 3, 2023 08:58AM
Aug 25, 2023 08:58AM First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial
Aug 10, 2023 08:58AM
Jul 4, 2023 08:55AM
May 24, 2023 09:03AM
Feb 9, 2023 09:03AM
Nov 21, 2022 09:04AM
Oct 6, 2022 09:04AM
Sep 5, 2022 09:09AM Recruitment opens for Phase II trial in prostate cancer with Cu-64 SAR-Bombesin in the US
Aug 23, 2022 09:04AM

328,702 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All